Improved Product Quality of Biosimilars in the Cellca CHO Expression Platform
15th December 2017
Category: Biosimilars
Tags: biosimilar development, Cellca CHO Expression Platform
By: Cornelia Lindner - Team Leader, Dr Christoph Zehe - Lead Scientist, Johannes Wirth - Scientist, Marina Putanko - Scientist,
Due to the high number of patent expirations for first generation biopharmaceuticals, the production of biosimilars is a fast growing market. Biosimilars require finger-print like similarity to their originator drug with respect to product quality. One important aspect of product quality is a comparable glycosylation pattern, as glycosylation influences serum clearance, immunogenicity, as well as More
Promoter Evaluation in the Cellca CHO DG44 Expression System
4th December 2017
Category: Cell Line Development
Tags: Cell line development, Cellca CHO Expression Platform
By: Ann-Catherin Leroux - Scientist, Dr Christoph Zehe - Lead Scientist,
One key component of the powerful Cellca Expression Platform is the expression vector. We have carefully selected its genetic elements to allow: freedom to operate high level expression of monomeric and dimeric products (e.g. IgG-type antibodies, Fc-Fusion, bispecifics) enhanced, stable expression by optimized S/MAR elements increased secretion by optimized signal peptide As a next step More